@Article{Stachowiak2010,
journal="Menopause Review/Przegląd Menopauzalny",
issn="1643-8876",
volume="9",
number="1",
year="2010",
title="17ß-oestradiol (1 mg) plus drospirenone (2 mg) in hormonal therapy of postmenopausal period",
abstract="Low-dose oral MHT combining 1 mg oestradiol (E2) and 2 mg drospirenone (DRSP) is effective in alleviating climacteric and urogenital symptoms, prevents endometrial hyperplasia, reduces the risk of osteoporosis, and has a positive influence on lipid profile, carbohydrate metabolism, arterial pressure and female quality of life. This safe type of MHT can be a drug of first choice for the big group of women after menopause.",
author="Stachowiak, Grzegorz
and Pertyński, Tomasz",
pages="1--4",
url="https://www.termedia.pl/17ss-oestradiol-1-mg-plus-drospirenone-2-mg-in-hormonal-therapy-of-postmenopausal-period,4,14196,1,1.html"
}